Latest Articles

Publication Date
Robotic-assisted excision of an accessory cavitated uterine malformation with indocyanine green assessment of the uterine cavity.

To highlight the presentation and management of a patient with dysmenorrhea caused by an accessory cavitated uterine malformation (ACUM) while also summarizing the current evidence regarding this pathology.

Published: Jan. 6, 2025, midnight
Association between endometriosis and congenital uterine malformations: A single-center retrospective study.

The association between endometriosis and congenital uterine anomalies (CUAs) has been discussed for decades, but existing evidence about this association is scarce. The aim of our study is to evaluate …

Published: Jan. 3, 2025, midnight
Decidualized ovarian and rectouterine deep endometriosis disguised as malignancy in the second-trimester of pregnancy: A case report.

Pregnancy is a special time during which some benign hormonally-responsive lesions could grow and mimic malignancy on clinical evaluation and imaging. Though decidualization of ovarian endometrioma has been reported, little …

Published: Jan. 3, 2025, midnight
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial …

Published: Dec. 31, 2024, midnight
Nanoceria as a non-steroidal anti-inflammatory drug for endometriosis theranostics.

Endometriosis, the growth of endometrial-like tissue outside the uterus, causes chronic pain and infertility in 10 % of reproductive-aged women worldwide. Unfortunately, no permanent cure exists, and current medical and …

Published: Dec. 30, 2024, midnight
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan - springermedicine.com

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced …

Published: Dec. 28, 2024, 12:47 p.m.
Exploratory Analysis of Radiomics and Pathomics in Uterine Corpus Endometrial Carcinoma - Nature.com

Exploratory Analysis of Radiomics and Pathomics in Uterine Corpus Endometrial Carcinoma Nature.com

Published: Dec. 28, 2024, 3:08 a.m.
DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER.

Endosalpingiosis occurs in relatively young women. The incidence of endosalpingiosis exceeds that of other diseases affecting female tissues. As endosalpingiosis is a benign tumor, several women with endosalpingiosis are asymptomatic. …

Published: Dec. 28, 2024, midnight
TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway - Journal of Translational Medicine

TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway Journal of Translational Medicine

Published: Dec. 27, 2024, 1:02 p.m.
Knowledge of the Benefits and Risks of Oral Contraceptive Use Among Women of Reproductive Age in Western Saudi Arabia: A Descriptive Cross-Sectional Study.

For women of reproductive age, oral contraceptives (OCs) are a well-liked and practical way to control pregnancy. OCs are also used to treat acne, irregular uterine bleeding, and premenstrual syndrome. …

Published: Dec. 26, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!